Celltrion

Celltrion is a South Korean biopharmaceutical company headquartered in Incheon, South Korea. It specializes in the development, manufacturing, and commercialization of biosimilars and novel biologic drugs.

Founded in 2002, Celltrion has focused on creating affordable versions of complex biologic medications, primarily in the areas of oncology, autoimmune diseases, and infectious diseases. The company utilizes mammalian cell culture technology for the production of its biosimilars.

Key products developed and marketed by Celltrion include biosimilars of infliximab (Remsima/Inflectra), rituximab (Truxima), and trastuzumab (Herzuma). These biosimilars offer cost-effective alternatives to the original branded biologics, expanding patient access to essential therapies.

Celltrion has a global presence, with its products marketed in numerous countries through partnerships and direct sales channels. The company continues to invest in research and development to expand its pipeline of biosimilars and novel biologics.

In addition to biosimilars, Celltrion has also developed and commercialized novel biologic drugs, including treatments for COVID-19. The company's research and manufacturing capabilities are supported by its state-of-the-art facilities and a team of experienced scientists and engineers.

Celltrion is publicly traded on the Korea Exchange (KRX: 068270). Its growth has been significant in the biopharmaceutical industry, contributing to increased competition and affordability in the biologics market.